Skip to main content
. 2021 Dec 10;8:795624. doi: 10.3389/fcvm.2021.795624

Figure 1.

Figure 1

Unfavorable outcome in COVID-19 is associated with declining platelet activity. (A) Study design: 110 patients admitted to the primary COVID-19 hospital in Vienna, Austria, were included in this longitudinal study within 72 h after hospital admission and prospectively analyzed. Blood was collected every 2-3 days over 1 week to determine platelet function and elucidate outcome-specific differences. (B,C) Platelet activation upon study entry at (B) basal condition and (C) after stimulation with 6μM ADP (15 min) was assessed in 97 patients upon hospital admission by quantifying surface CD62P expression and GPIIb/IIIa activation (PAC1 antibody binding). (D) Basal platelet activation was monitored over the span of 1 week after study. Asterisks (*) indicate significant differences to uncomplicated (orange: ICU; red: death), section signs (§) indicated significant differences between ICU and death. (E) Correlation of basal CD62P expression and GPIIb/IIIa activation of platelets. n = 97 patients. *p < 0.05, **p < 0.01, ****p < 0.0001; §p < 0.05, §§§p < 0.001.